INT196191

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.14
First Reported 2006
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 7
Total Number 8
Disease Relevance 5.84
Pain Relevance 0.25

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Mrgpre) plasma membrane (Mrgpre) molecular_function (Mrgpre)
cellular_component (Mrgpre) biological_process (Mrgpre) signal transducer activity (Mrgpre)
Mrgpre (Mus musculus)
Pain Link Frequency Relevance Heat
imagery 18 81.96 Quite High
positron emission tomography 15 81.24 Quite High
fibrosis 22 78.60 Quite High
agonist 10 5.00 Very Low Very Low Very Low
palliative 9 5.00 Very Low Very Low Very Low
Pain 7 5.00 Very Low Very Low Very Low
Somatostatin 6 5.00 Very Low Very Low Very Low
tolerance 5 5.00 Very Low Very Low Very Low
cva 4 5.00 Very Low Very Low Very Low
alcohol 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cancer 232 99.00 Very High Very High Very High
Toxicity 48 98.00 Very High Very High Very High
Cholangiocarcinoma 70 97.80 Very High Very High Very High
Prostate Cancer 112 97.32 Very High Very High Very High
Sarcoma 140 97.20 Very High Very High Very High
Liver Failure 5 96.64 Very High Very High Very High
Vomiting 2 92.72 High High
Appetite Loss 3 91.04 High High
Hypersplenism 1 88.56 High High
Pressure And Volume Under Development 11 87.40 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
demonstrate the utility of IORT as a boost to EBRT and a means of
EBRT Binding (boost) of
1) Confidence 0.14 Published 2006 Journal Sarcoma Section Body Doc Link PMC1557794 Disease Relevance 0.53 Pain Relevance 0.07
intent of the study was to administer IORT as a boost to EBRT,
EBRT Binding (boost) of
2) Confidence 0.12 Published 2006 Journal Sarcoma Section Body Doc Link PMC1557794 Disease Relevance 0.46 Pain Relevance 0
It

is our institution's policy to use IORT as a boost to EBRT for all

EBRT Binding (boost) of
3) Confidence 0.12 Published 2006 Journal Sarcoma Section Body Doc Link PMC1557794 Disease Relevance 0.47 Pain Relevance 0.07
unrelated causes before receiving EBRT.
EBRT Binding (receiving) of
4) Confidence 0.12 Published 2006 Journal Sarcoma Section Body Doc Link PMC1557794 Disease Relevance 0.66 Pain Relevance 0
The possible mechanism of ADT–EBRT interaction in that study was the diminished growth velocity of the surviving PC cells after neoadjuvant ADT.
EBRT Binding (interaction) of associated with prostate cancer
5) Confidence 0.12 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004567 Disease Relevance 0.63 Pain Relevance 0
Other more clinical observations shed some light on ADT–EBRT interactions.
EBRT Binding (interactions) of
6) Confidence 0.12 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004567 Disease Relevance 0.58 Pain Relevance 0
BED is the product of the total physical dose multiplied by the “relative effectiveness”, which takes into account radiobiological parameters such as dose rate, radionuclide decay and tumour cell repair time, and allows direct quantitative comparison with EBRT.
EBRT Binding (comparison) of associated with cancer
7) Confidence 0.04 Published 2007 Journal Eur J Nucl Med Mol Imaging Section Body Doc Link PMC1914264 Disease Relevance 0.50 Pain Relevance 0.11
Results of the present study demonstrate that EBRT was associated with improving survival in patients with unresectable ICC.
EBRT Binding (associated) of associated with cholangiocarcinoma
8) Confidence 0.01 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2949805 Disease Relevance 2.02 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox